Cardium Reports on Recent Highlights and Financi...( disease. -- Launch of InnerCo...),Health

disease.

-- Launch of InnerCool's new CoolBlue(TM) surface temperature modulation

system, which is designed to provide effective patient temperature

control in less acute patients or in clinical settings best suited to

prolonged temperature management.

-- Completion of development of InnerCool's next-generation RapidBlue(TM)

endovascular cooling system, including an enhanced console and

disposable catheter, which is designed to cool patients rapidly and

controllably, and provide effective rewarming as well as cooling.

-- Publication in the Journal of American College of Cardiology of

positive findings from a pooled by-patient analysis of the AGENT-3 and

AGENT-4 Phase 2b/3 clinical trials for Generx. Among the findings

reported, a pre-specified analysis showed significant improvements in

multiple clinical measures of heart disease among women who received

Generx(TM) as compared to women in the placebo control group.

-- Completion of a $21.5 million equity financing with institutional and

other accredited investors and listing on the American Stock Exchange

(AMEX) under the new trading symbol CXM.

-- Licensing agreement with the University of Texas Health Science Center

at Houston for the clinical research, development and

commercialization of Caffeinol as a potential therapeutic for use in

acute ischemic stroke patients. A Phase 2a study has been proposed to

the National Institute of Neurological Disorders and Stroke, part of

the National Institutes of Health (NIH), to assess the safety and

efficacy of induced hypothermia and Caffeinol, both individually and

in combination, in an estimated 400 patients presenting within three

hours of an acute stroke.

-- Initiation of pre-clinical studies supported by
'/>"/>